Vivos Therapeutics (VVOS) Gross Margin (2020 - 2025)
Historic Gross Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 58.04%.
- Vivos Therapeutics' Gross Margin fell 24200.0% to 58.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 55.74%, marking a year-over-year decrease of 60600.0%. This contributed to the annual value of 60.0% for FY2024, which is 700.0% up from last year.
- According to the latest figures from Q3 2025, Vivos Therapeutics' Gross Margin is 58.04%, which was down 24200.0% from 55.24% recorded in Q2 2025.
- Vivos Therapeutics' 5-year Gross Margin high stood at 80.59% for Q2 2021, and its period low was 50.03% during Q1 2025.
- Moreover, its 5-year median value for Gross Margin was 60.59% (2023), whereas its average is 62.76%.
- In the last 5 years, Vivos Therapeutics' Gross Margin tumbled by -187300bps in 2022 and then skyrocketed by 75400bps in 2024.
- Vivos Therapeutics' Gross Margin (Quarter) stood at 70.71% in 2021, then dropped by -15bps to 60.35% in 2022, then rose by 7bps to 64.32% in 2023, then dropped by -12bps to 56.71% in 2024, then grew by 2bps to 58.04% in 2025.
- Its last three reported values are 58.04% in Q3 2025, 55.24% for Q2 2025, and 50.03% during Q1 2025.